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Pharmacogenomics: 
Privacy in the Era of Personalized Medicine 
Berrie Rebecca Goldman* 
I. INTRODUCTION 
¶1 Pharmacogenomics is defined as “the use of associations between the effects of 
drugs and genetic markers to develop genetic tests that can be used to fine-tune patient 
diagnosis and treatment.”1  Researchers in the field of pharmacogenomics study genes 
that produce drug-metabolizing enzymes in the body.2  Utilizing an individual’s genetic 
profile in prescribing medications for various diseases will prevent unwanted side-effects 
and allow drugs to work more efficiently.3  Pharmacogenomics requires the analysis of an 
individual’s genetic information and the comparison of that genetic information, along 
with reactions to specific drugs, to the information and reactions of others to determine 
which drugs most effectively treat a given disease or condition.4  Although 
pharmacogenomics is not yet widely used, this technology is likely to someday change 
the way physicians practice medicine and the expectations of patients in seeking 
treatment.  Pharmacogenomics may not only benefit patients by improving physicians’ 
ability to more accurately provide treatment for diseases and illnesses, but this new 
technology may potentially affect patients negatively by risking the individual’s right to 
privacy. 
¶2 The issue of privacy arises as a result of the inherently personal nature of each 
individual’s genetic makeup.5  Some people may be reluctant to share this information 
with physicians and medical researchers, fearing that they or their family members will 
be discriminated against by insurers if they test positive for a genetic disease.6 
 
* Berrie Goldman is a 2006 Juris Doctor candidate at Northwestern University School of Law.  She 
received her Bachelor of Arts degree in Biomedical Physics from California State University, Northridge, 
and her Bachelor of Arts degree in History and English from the University of California, Los Angeles. 
1 STUART M. BROWN, ESSENTIALS OF MEDICAL GENOMICS 253 (2003).  Pharmacogenetics, a parallel 
field, involves the study of how genes affect the way people respond to drugs.  The difference between 
pharmacogenomics and pharmacogenetics is slight.  Some scientists consider these two fields to be 
equivalent, and the terms “pharmacogenomics” and “pharmacogenetics” are sometimes used 
interchangeably.  LEON SHARGEL ET AL., APPLIED BIOPHARMACEUTICS & PHARMACOKINETICS 355 (2005). 
2 SHARGEL, supra note 1. 
3 BROWN, supra note 1. 
4 See B. Michael Silber, Pharmacogenomics, Biomarkers, and the Promise of Personalized Medicine, in 
PHARMACOGENOMICS 14 (Werner Kalow et. al. eds., 2001). 
5 LAURINDA BEEBE HARMAN, ETHICAL CHALLENGES IN THE MANAGEMENT OF HEALTH INFORMATION 
275 (2001). 
6 See, e.g., id. at 274. 
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¶3 Each individual has genetic markers, which serve as points of reference.7  These 
markers are DNA or protein sequences that are located on a specific region of a 
chromosome.8  The developing technology behind pharmacogenomics utilizes these 
genetic markers to evaluate how drugs will react in an individual with a specific genetic 
profile.9  Pharmacogenomics seeks to determine variations in drug responses by 
monitoring genetic changes (alterations in genotype) or physical changes (alterations in 
phenotype) in individuals and groups of patients in order to determine the most efficient 
and least adverse treatment for disease.10 
¶4 Pharmacogenomics, as a way of enabling physicians to better treat their patients, 
inherently involves comparison and analysis of a large number of genetic profiles.11  In 
order to best evaluate which course of treatment to follow, and more specifically which 
drug will work best for a patient’s condition, the physician must be able to evaluate other 
patients’ responses to treatment options or drugs available for that condition.  To provide 
the most comprehensive access to genetic profiles, there must be a database containing 
that information which physicians can access to determine the likelihood of adverse drug 
reactions, side-effects, and efficacy.12  Disclosure of this type of personal information 
inevitably leads to privacy issues, as individuals are concerned about sharing their genetic 
profiles with the general population.13 
¶5 This new method of cataloguing and disseminating genetic information is likely to 
increase the privacy concerns already associated with genetic research and genetic 
testing.14  Several studies have shown concern among United States citizens regarding 
discrimination and loss of privacy as a result of sharing their genetic information, and 
many cite these concerns as reasons for not participating in medical research studies.15  
Pharmacogenomics requires the examination of large numbers of genetic profiles for 
success, but individuals will be reluctant to participate unless measures are taken to 
ensure confidentiality and restrict the possibility of discriminatory uses of genetic 
information.16 
¶6 This comment will first set forth the technology of pharmacogenomics and its 
future applicability to medical treatment.  Second, it will propose a solution to the privacy 
issues resulting from the development of a pharmacogenomics database.  This comment 
 
7 LELAND H. HARTWELL ET AL., GENETICS: FROM GENES TO GENOMES 113 (2000). 
8 Patricia A. Peyser & Trudy L. Burns, Approaches to Quantify the Genetic Component of and Identify 
Genes for Complex Traits, in HUMAN GENOME EPIDEMIOLOGY: A SCIENTIFIC FOUNDATION FOR USING 
GENETIC INFORMATION TO IMPROVE HEALTH AND PREVENT DISEASE 43 (Muin J. Khoury et al. eds., 2004). 
9 BROWN, supra note 1, at 185-86. 
10 SHARGEL, supra note 1, at 360. 
11 See Silber, supra note 4. 
12 Id. 
13 Id.; see also HARMAN, supra note 5. 
14 See HARMAN, supra note 5. 
15 A 1995 Harris Poll found that “86% of those surveyed were concerned that insurers and employers 
might use genetic information against them.”  In addition to discrimination in insurance and the workplace, 
the survey respondents expressed concern regarding the confidentiality of genetic information used for 
research purposes.  In 1997, one-third of the women invited to participate in a study of gene mutations 
leading to breast cancer declined participation, citing fear of discrimination and loss of confidentiality. Id. 
at 275. 
16 See id. at 276. 
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seeks to create a template for federal legislation protecting an individual’s right to 
privacy in light of the development of pharmacogenomics technology. 
¶7 The technological development of pharmacogenomics, examined in Part II, 
requires a database to compare and catalog genetic profiles of individuals suffering from 
various conditions and undergoing treatment for those conditions.17  Establishing a 
database poses issues of confidentiality and privacy, as an individual’s information is 
made available to the public, or at least to specific classes of professionals.18  The Health 
Insurance Portability and Accountability Act (“HIPAA”) is the current manifestation of 
federal protection of patient privacy rights in the United States,19 but this legislation may 
not be enough to protect individuals with the creation of a pharmacogenomics database 
containing genetic profiles.  Part III analyzes the inadequacies of HIPAA in light of the 
development of pharmacogenomics and increased usage of genetic databases.  Part IV 
will discuss how federal law may be tailored to balance patient privacy and the 
dissemination of information for the public good.  This comment proposes, as a primary 
solution to concerns about genetic privacy, federal legislation that expands the scope of 
HIPAA to specifically protect information compiled in a pharmacogenomics database, in 
addition to providing incentives for patients to contribute to the public welfare by sharing 
their genetic profiles. 
II. BACKGROUND - PHARMACOGENOMICS: WHAT IS IT AND HOW DOES IT WORK? 
A. History of Pharmacogenomics 
¶8 Pharmacogenomics has been around in some form since the 1930s.20  In 1902, 
Archibald Garrod first asserted the hypothesis that genetic variations could cause adverse 
biological reactions when chemical substances were ingested.21  He also suggested that 
enzymes22 were responsible for detoxifying foreign substances, and that some people do 
not have the ability to eliminate certain foreign substances from the body because they 
lack enzymes required to break down these materials.23 
¶9 The first pharmacogenetic study took place in 1932, when the inability to taste a 
chemical compound known as phenylthiocarbamide was linked to an autosomal recessive 
 
17 See Silber, supra note 4. 
18 These classes of professionals include physicians and researchers, and may also include insurance 
companies and employers.  See infra Part IV.c for a discussion of who should have access to a database 
created to support pharmacogenomics. 
19 Health Insurance Portability and Accountability Act, Pub. L. No. 104-191, 110 Stat. 1936 (1996). 
20 David L. Veenstra, The Interface Between Epidemiology and Pharmacogenomics, in HUMAN 
GENOME EPIDEMIOLOGY: A SCIENTIFIC FOUNDATION FOR USING GENETIC INFORMATION TO IMPROVE 
HEALTH AND PREVENT DISEASE, supra note 8, at 234. 
21 Laviero Mancinelli et al., Pharmacogenomics: The Promise of Personalized Medicine, 2 AAPS J. 1, 3 
(2000), available at http://www.aapspharmsci.org/articles/ps0201/ps020104/ps020104.pdf.  Garrod was a 
British physician working at St. Bartholomew’s Hospital in London during the late 19th and early 20th 
centuries and is best known for demonstrating that the genetic disorder alkaptonuria results from the 
recessive allele of an autosomal gene, which he called an “inborn error of metabolism.”  HARTWELL, supra 
note 7, at 201. 
22 An enzyme is defined as a protein within a living organism that increases the rate of speed of a 
chemical reaction, without being used up during the reaction. KENNETH R. MILLER & JOSEPH LEVINE, 
BIOLOGY 75 (2000). 
23 Mancinelli, supra note 21. 
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trait.24 An autosome is a chromosome that does not participate in sex determination,25 and 
therefore refers to all the cells in the body except for sperm and eggs.  Recessive traits are 
described as follows: each person has two genes that code for a particular trait — one is 
inherited from the mother and one is inherited from the father.26  If a person inherits two 
different alternative forms of a gene, called alleles, the trait that is expressed physically as 
a phenotype is the dominant trait, while the one not expressed is a recessive trait.27  
Examples of recessive traits include hitchhikers thumb and blue eyes. 
¶10 In the 1932 study, participants with two recessive alleles were unable to produce a 
particular enzyme that allowed them to taste the phenylthiocarbamide chemical.28  This 
determination that the inability to taste was linked to an autosomal recessive trait 
demonstrated that certain chemicals react differently depending on genetic 
predispositions.29 
¶11 In the 1940s and 1950s, scientists first began to note “variable drug responses” in 
people taking various preventive medications.30  Drug reactions based on inherited traits 
were first recorded during World War II, when some soldiers developed anemia after 
receiving doses of the anti-malarial drug primaquine.31  Later studies confirmed that the 
anemia was caused by a genetic deficiency of the glucose-6-phosphate dehydrogenase 
enzyme.32  Similar reactions to succinlcholine and isoniazid were studied, and revealed 
that deficiencies in enzymes led to an inability to metabolize those drugs.33  After 
studying adverse drug reactions to primaquine, succinlcholine, and isoniazid, Arno 
Moltulsky34 proposed in 1957 that inherited traits may not only lead to adverse drug 
reactions, but may also affect whether the drugs actually work.35 
¶12 In recent decades, further progress has been made in isolating genetic variations in 
major drug-metabolizing enzymes, including cytochrome P450.36  Scientists first began 
to study cytochrome P450 when some patients experienced a severe decline in blood 
pressure while taking debrisoquin, an anti-hypertensive drug.  The study revealed that 
these patients had two recessive alleles for the enzyme, resulting in an inability to 
 
24 Id. 
25 BROWN, supra note 1, at 238. 
26 U.S. National Library of Medicine, National Institutes of Health, Department of Health & Human 
Services, Help Me Understand Genetics 11 (February 25, 2005), available at 
http://ghr.nlm.nih.gov/dynamicImages/understandGenetics.pdf. 
27 See id. at 51-52; HARTWELL, supra note 7, at 17, 19. 
28 Mancinelli, supra note 21. 
29 Id. 
30 The studies performed evaluated individuals taking isoniazid (to prevent tuberculosis), succinlcholine 
(a muscle relaxant), and the anti-malaria drug primaquine.  See Veenstra, supra note 20. 
31 Mancinelli, supra note 21. 
32 Id.  The United States Army determined that approximately 10% of African Americans have the 
polymorphic allele of glucose-6-phosphate dehydrogenase, leading to the deficiency causing anemia.  
BROWN, supra note 1, at 186. 
33 Veenstra, supra note 20.  The studies revealed that reactions to succinlcholine resulted from a 
deficiency in the N-acetyl transferase enzyme, while reactions to isoniazid resulted from a deficiency in the 
pseudocholinesterase enzyme. 
34 Dr. Motulsky is currently a senior faculty member at the University of Washington, and is continuing 
his research in human genetics. UW Genome Sciences Faculty, 
http://www.gs.washington.edu/faculty/motulsky.htm (last visited Nov. 1, 2005). 
35 Mancinelli, supra note 21. 
36 Cytochrome P450 is also referred to as CYP2D6.  Veenstra, supra note 20; Mancielli, supra note 21. 
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metabolize the drug.37  Approximately ten percent of the population metabolizes 
cytochrome P450 poorly, experiencing adverse effects and reduced drug uptake when 
they take drugs in the family of chemicals metabolized by the enzyme.38  The evaluation 
of cytochrome P450 has led to the identification and characterization of many other drug-
metabolizing enzymes.39 
¶13 Although pharmacogenomics continues to be a burgeoning field of technology, it is 
unclear where this new technology will ultimately lead.  Currently, research in 
pharmacogenomics is primarily focused on preventing adverse drug reactions through the 
analysis of the relationship between drug-metabolizing enzymes and the chemical 
compounds that those enzymes break down.40  In the future, pharmacogenomics may also 
be used to determine which receptors are best equipped to transport particular chemical 
compounds into the cell for the purpose of treating a disease or condition.41  Such an 
application would allow greater “personalization” of medicine by tailoring drugs to an 
individual’s genetic profile.42  Although evaluating receptor participation in drug uptake 
is a promising area of research, it is likely that research in the near future will continue to 
focus on the evaluation of polymorphisms43 in drug-metabolizing enzymes.44 
B. Example of Pharmacogenomics Applicability: Birth Control Pills 
¶14 The research carried out by Garrod, Moltulsky, and others illustrates the 
importance of genetic factors in determining which drugs will work most effectively and 
which will cause adverse reactions.45  However, pharmacogenomics can also aid people 
without diseases or enzyme deficiencies.  The potential negative effects of oral 
contraceptives, provides such an example: women who take birth control pills are 
generally young, healthy individuals looking to prevent pregnancy or regulate hormones 
for other reasons.46  Although taken by healthy individuals, birth control pills may cause 
severe side-effects including blood clots and stroke, which could lead to death.47 
¶15 The increasing use of pharmacogenomics will enable physicians to identify risk 
factors in a woman’s genetic profile, which may be examined in conjunction with 
 
37 Veenstra, supra note 20. 
38 SHARGEL, supra note 1, at 361-363. 
39 Veenstra, supra note 20. 
40 SHARGEL, supra note 1, at 360. 
41 For an in-depth discussion of the use of receptors in pharmacogenomics, see Wendell W. Weber, 
Pharmacogenetics — Receptors, in PHARMACOGENOMICS, supra note 4, at 51. 
42 Veenstra, supra note 20. 
43 A polymorphism refers to a change in a nucleotide base at a given position on the genome, “when the 
frequency of the most common base at that position is [greater than] 99%.”  BROWN, supra note 1, at 103. 
44 Lars Noah, The Coming Pharmacogenomics Revolution: Tailoring Drugs to Fit Patients’ Genetic 
Profiles, 43 JURIMETRICS J. 1, 9 (2002). 
45 See Veenstra, supra note 20, at 235. 
46 See Jan Vandenbroucke, et. al., Oral Contraceptives and the Risk of Venous Thrombosis, 344 NEW 
ENG. J. MED. 1527, 1531-32 (2001). 
47 Recent studies have indicated that the risk of blood clots, also known as venous thrombosis, increases 
three to six times for women using oral contraceptives over the risk to those who do not use oral 
contraceptives.  Id. at 1527.  Litigation against both physicians and pharmaceutical companies has resulted.  
See Brochu v. Ortho Pharmaceutical Corp., 642 F.2d 652 (1st Cir. 1981); Spensieri v. Lasky, 258 A.D.2d 
754 (N.Y. 1999); MacDonald v. Ortho Pharmaceutical Corp., 475 N.E.2d 65 (Mass. 1985). 
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environmental factors to determine whether the use of birth control pills is likely to result 
in potentially severe side effects.48  Research in this area has already begun.  Scientists 
have recently uncovered a genetic mutation, called Factor V Leiden, that increases a 
woman’s risk of blood clots, especially when paired with oral contraceptives.49  Factor V 
Leiden is a mutation of the Factor V gene, a gene that codes for a glycoprotein circulating 
in the blood.50  This mutation is the most common inherited blood-clotting disorder in the 
United States, affecting 5% of Caucasians and 1.2% of African-Americans.51  DNA tests 
can determine whether an individual is homozygous or heterozygous for the Factor V 
Leiden mutation,52 thus increasing her chances of developing blood clots.53  By using this 
genetic information, physicians prescribing oral contraceptives may be able to reduce 
their patients’ risk of adverse drug reactions like blood clots and stroke.54 
C. Method to the Madness: The Technology Behind Pharmacogenomics 
¶16 Understanding the scientific processes underlying the technology of 
pharmacogenomics requires a short cell biology lesson.  Each living organism has a 
unique genetic profile comprised of genes that code for the production of proteins.55  
Proteins known to affect drug metabolism fall into three categories: (1) proteins that 
degrade or activate chemical compounds; (2) proteins that interact with a target molecule 
to prevent drugs from binding to a receptor; or (3) proteins that regulate metabolic 
pathways that affect drug function.56 
¶17 Some proteins themselves act as receptors, and therefore receive chemical signals 
from outside the cell.57  These proteins transport molecules into and out of cells, thereby 
regulating which materials are allowed to enter the cell.58  Receptors, by virtue of their 
gate-keeping function, determine which drugs can enter the cell and fight disease.59  
 
48 See Vandenbroucke, supra note 48, at 1532. 
49 Jan P. Vandenbroucke et al., Factor V Leiden, Oral Contraceptives, and Deep Vein Thrombosis, in 
HUMAN GENOME EPIDEMIOLOGY: A SCIENTIFIC FOUNDATION FOR USING GENETIC INFORMATION TO 
IMPROVE HEALTH AND PREVENT DISEASE, supra note 8, at 322. 
50 Id. at 324-325. 
51 MedicineNet.com, http://www.medterms.com/script/main/art.asp?articlekey=25022 (last visited Oct. 
24, 2005).  See also Vandenbroucke, supra note 51, at 326 (prevalence of Factor V Leiden is approximately 
5% in Caucasians worldwide, but is virtually absent in African and Asian populations). 
52 An individual is homozygous for a gene if that individual possesses two identical copies of each gene 
coding for an expressed trait.  An individual has a heterozygous genotype when that person has two 
different forms of a gene that code for an expressed trait.  HARTWELL, supra note 7, at 19.  The presence of 
the mutation, either in homozygous (two copies of the mutation) or heterozygous (one copy of the 
mutation) form, increases the probability that a woman will develop blood clots while taking oral 
contraceptives.  See Vandenbroucke, supra note 51, at 326. 
53 Vandenbroucke, supra note 51, at 326. 
54 See Vandenbroucke, supra note 48, at 1532. 
55 HARTWELL, supra note 7, at G-10. 
56 BROWN, supra note 1, at 186.  The drug-metabolizing enzymes discussed supra Part II.a fall into the 
third protein category. 
57 HARTWELL, supra note 7, at 2. 
58 See ARTHUR M. LESK, INTRODUCTION TO PROTEIN SCIENCE: ARCHITECTURE, FUNCTION AND 
GENOMICS 25 (2004). 
59 The genetic sequence that codes for a protein also codes for its shape.  Shape is an important feature 
of a protein, as it is this shape that determines how the protein will function.  HARTWELL, supra note 7, at 
203. 
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Receptors on the surface of cells vary depending on genotype, as DNA determines the 
characteristics of proteins.60  Because of this variance, people react differently to different 
medications, as one person’s receptors may allow a chemical into the cell while another 
person’s receptors may prevent the cell from absorbing that drug.61 
¶18 In addition to determining which chemicals to allow into the cell, some proteins 
serve to alter the shape of drug molecules, effectively turning them “on.”62  Evaluating 
which genotypes allow chemicals to be turned on, and which keep the drugs “off,” will 
allow physicians to determine the medications that will work for their patients.63  
Geneticists can now identify single genetic markers in an individual’s genetic profile that 
code for drug-interaction genes, which will ultimately increase physicians’ ability to 
prescribe the appropriate medication without the risk of side-effects or the possibility of 
failed treatment.64 
D. Pharmacogenomics Versus Genetic Testing 
¶19 Pharmacogenomics is considerably different from genetic testing because it 
requires an evaluation of a person’s entire genetic profile, not just the presence or 
absence of single genetic markers.65  Genetic testing was previously conducted under the 
theory that most diseases were monogenic, meaning that one gene caused each disorder.66  
Now, the general belief has shifted toward the concept of polygenic disorders, where 
multiple mutated genes contribute to a single disorder.67  Due to this shift in theory, 
genetic testing now involves analyses of multiple portions of the genome, but still does 
not require analysis of the complete genetic profile.68  Although both pharmacogenomics 
and genetic testing involve comparing genes to determine the likelihood of future disease, 
only pharmacogenomics compares whole genetic profiles to evaluate drug efficacy and 
potential adverse reactions.69 
¶20 The success of the pharmacogenomics technology therefore depends on compiling 
complete genetic profiles that will allow physicians to compare thousands of single 
nucleotide polymorphisms (“SNPs”) 70 from one individual with those of another 
individual.71  A comparison of these markers across the entire genome will enable 
physicians and researchers to “screen groups of patients receiving a specific drug and 
then correlate good and poor drug efficacy and the occurrence of specific side effects 
 
60 Id. at 2. 
61 See LESK, supra note 60. 
62 National Institutes of Health, Medicines for You, available at 
http://publications.nigms.nih.gov/medsforyou/MedsForYou.pdf. 
63 Id. 
64 BROWN, supra note 1, at 186. 
65 Id. 
66 SHARGEL, supra note 1, at 360. 
67 Id. 
68 See BROWN, supra note 1, at 187-88. 
69 Silber, supra note 4, at 24. 
70 Single Nucleotide Polymorphisms, also known as SNPs, are defined as “single base pair mutations 
that appear at frequencies above 1% in the population.”  BROWN, supra note 1, at 257.  In plain English, an 
SNP is one change in the sequence of amino acids that comprise a strand of DNA.  SNPs are frequently 
used to identify genes related to disease.  Peyser, supra note 8, at 44. 
71 BROWN, supra note 1, at 187. 
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with individual SNP markers.”72  As a result of these comparisons, physicians and 
researchers may determine which genetic markers influence adverse drug reactions and 
which genetic markers increase drug efficacy.73 
III. ANALYSIS 
¶21 In the near future, pharmacogenomics is likely to become the standard used by 
physicians to prescribe medications to their patients.74  Prior to the full development of 
this technology, it is important to consider its privacy implications and what should be 
done to protect the confidentiality of each patient’s genetic information.75  The sections 
below evaluate the need for a database containing genetic information, the current 
statutory system for genetic information privacy in the United States, and how the current 
system should be revised and expanded in order to protect confidentiality of genetic 
information as pharmacogenomics progresses. 
A. The Pharmacogenomics Database 
¶22 Pharmacogenomics cannot succeed unless a system is developed where a large 
number of genetic profiles and individual responses to drugs may be compared to 
evaluate drug efficacy and potential adverse reactions.76  The most efficient way to 
evaluate and compare genetic profiles and individual drug response is to develop a 
national database containing this information.77  However, the development of such a 
database presents significant issues of privacy and confidentiality.  Many patients are 
concerned that their information may be used without their consent and they will be 
discriminated against in areas of insurance and employment.78 
¶23 The key to a beneficial pharmacogenomics program is the development of a 
database, linking data obtained in the lab with data obtained from patients.79  Such a 
database would enable scientists to compare large numbers of patient profiles and access 
information gleaned from laboratory research.80  Although pharmacogenomics has great 
potential to revolutionize medicine, if genetic information is kept private, the technology 
will not succeed.81 
¶24 The current manifestation of a pharmacogenomics database exists in the 




74 See Darrell L. Ellsworth & Christopher J. O’Donnell, Emerging Genomic Technologies and Analytic 
Methods for Population- and Clinic-Based Research, in HUMAN GENOME EPIDEMIOLOGY: A SCIENTIFIC 
FOUNDATION FOR USING GENETIC INFORMATION TO IMPROVE HEALTH AND PREVENT DISEASE, supra note 
8, at 33. 
75 Silber, supra note 4. 
76 Silber, supra note 4. 
77 Id. 
78 See HARMAN, supra note 5, at 274-75; see also supra text accompanying note 15. 
79 Silber, supra note 4. 
80 Id. 
81 Id. 
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Institute of General Medical Science, a branch of the National Institutes of Health.82  The 
database is based on a project entitled the Pharmacogenomics Research Network83 and 
represents a synthesis of studies evaluating the functions of proteins, identifying 
polymorphisms, and assessing the relationship of genetic variants to clinical drug 
responses.84  The database includes information on a subject’s health, including history of 
disease, physical/physiologic characteristics,85 the drugs taken and the response to those 
drugs, as well as DNA sequences that may play a role in drug metabolism.86  PharmGKB 
currently contains data on 597 genes, sixty drugs, and eighteen diseases.87  PharmGKB 
contains no identifying personal information, and consists of only partial DNA sequences 
as opposed to full genetic profiles.88 
¶25 PharmGKB does not contain full genetic profiles, however, and will not be 
sufficient as pharmacogenomics becomes essential for treating diseases and conditions.  
Additionally, the fact that PharmGKB does not contain any identifying information could 
pose difficulties.  Although anonymity safeguards privacy, including some form of 
identifying information would allow for notification.  Notification may be necessary, or 
at least desired, as the database grows and increases the number of genetic markers 
known to affect drug metabolism.  Individuals may want to know if the drugs they are 
taking may be replaced by more effective treatment options.  In order for patients to 
receive the benefits of the database, there must be a way to notify them if information 
contained in the database suggests the drugs they are taking may be replaced by more 
effective treatment options. 
B. Privacy Concerns 
¶26 Developing a database containing genetic profiles poses a significant problem — 
privacy.  Patients may not want to share their genetic profiles for fear that they may be 
discriminated against by insurance companies, employers, and others.89  Similarly, 
making genetic information available to the public, or at least to a specific segment of the 
public, namely physicians, marks a decline in patient autonomy.90  Patients will not be 
 
82 Press Release, National Institutes of Health, NIH Renews Network Focused On How Genes Influence 
Drug Responses (Sept. 28, 2005) available at 
http://www.nigms.nih.gov/News/Results/20050928PGRN.htm (last visited Oct. 24, 2005). 
83 The NIH recently announced plans to expand the Pharmacogenomics Research Network over the next 
five years, and anticipates spending approximately $150 million on the project.  Id. 
84 BROWN, supra note 1, at 190. 
85 Physical characteristics available in the Pharmacogenomics Knowledge Base include height, weight, 
blood pressure, and other relevant characteristics.  Access to the Pharmacogenomics Knowledge Base may 
be found at http://www.pharmgkb.org. 
86 BROWN, supra note 1, at 190. 
87 These numbers are current as of October 10, 2005.  However, the number of genes, drugs, and 
diseases with primary information available in the PharmGKB database is rapidly expanding.  The numbers 
in each category have almost doubled over the past nine months.  Pharmacogenomics Knowledge Base, at 
http://www.pharmgkb.org/ (last visited October 24, 2005). 
88 BROWN, supra note 1, at 191. 
89 See HARMAN, supra note 5, at 274-75. 
90 Patient autonomy is a substantive principle of social justice, stating that “each person is in control of 
his own person, including his body and mind.”  This principle is often compared with the principle of 
beneficence, where “what is best for each person should be accomplished.”  These two principles may 
come into conflict when an individual wants something for himself that others believe is not best for him.  
N O RT H W ES T ERN  J O U RN A L O F  T ECH N O LO G Y  A N D  IN TE LL EC TU A L PRO P ER TY  [ 2 0 0 5  
 
92 
able to decide who has access to their personal information if it is freely accessible in a 
public database.91 
¶27 There are many other potential public costs of a national genetic database.  
Individuals will not consider sharing their information if the opportunity cost is too high.  
It may be difficult to persuade individuals to share their genetic information if they are 
concerned about the availability of insurance or employment when their profile reveals 
the potential for genetic disease.92  Additionally, individuals, especially older generations, 
may not clearly understand the technology and therefore may be less likely to participate 
in such a system.    
¶28 One potential comfort to patients is that privacy in pharmacogenomics should not 
be as much of a concern as privacy in genetic testing.93  Because genetic testing involves 
identification of potential disease-causing biomarkers, individuals may be understandably 
concerned about sharing this extremely private information with others.94  
Pharmacogenomics, however, focuses on responses to medication.95  This focus on 
medication, as opposed to a focus on potential development of diseases, should decrease 
apprehension regarding the sharing of information, as it is less likely to lead to 
discrimination in insurance or in the workplace. 
¶29 Nonetheless, the privacy concern raises the issue of whether individuals would be 
willing to share their genetic profiles with others to benefit the public.  If a significant 
percentage of the population were to donate their profiles to a pharmacogenomics 
database, the likelihood that researchers could successfully link drug responses to specific 
genetic characteristics would increase exponentially.96 On the other hand, if concerns 
about discrimination and misunderstanding of technology restrict sharing of genetic 
information, the pharmacogenomics database will ultimately be less efficient.97 
¶30 Greater participation in the database will ultimately lead to an increased 
opportunity for research to identify and isolate polymorphisms affecting drug 
metabolism.98  People should be willing to share their information because they and their 
family members will reap the future benefits of a database indicating which drugs will 
cause adverse reactions and which drugs will work most effectively for their conditions. 
 
FURROW ET AL., BIOETHICS: HEALTH CARE LAW AND ETHICS 229 (2001).  This issue is likely to arise in 
pharmacogenomics when someone declines the use of his profile for privacy reasons, even though it would 
be in his best interest and the best interest of society to contribute to research that will increase the 
effectiveness of drugs. 
91 The National Institutes of Health and various research groups have continued to push for public 
access to genetic information in recent years in order to improve the efficient dissemination of information 
and advancement of science.  For a discussion of public versus private databases, see Adam D. Marks and 
Karen K. Steinberg, The Ethics of Access to Online Genetic Databases: Private or Public?, 3 AM. J. 
PHARMACOGENOMICS 207 (2002). 
92 See HARMAN, supra note 5. 
93 Silber, supra note 4, at 24. 
94 See HARMAN, supra note 5, at 274-75. 
95 Silber, supra note 4, at 24. 
96 See id. at 14. 
97 See Henry T. Greely, Genotype Discrimination: The Complex Case for Some Legislative Protection, 
149 U. PA. L. REV. 1483, 1501 (2001). 
98 See Silber, supra note 4. 
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C. The Current Privacy Standard: HIPAA 
¶31 The Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) is the 
current federal health information privacy law in the United States.99  HIPAA protects the 
confidentiality of a patient’s medical information by limiting its collection, use, and 
disclosure.100 
¶32 Section 701(b)(1)(B) addresses genetic information.  It states that “[g]enetic 
information shall not be treated as a condition described in subsection (a)(1) in the 
absence of a diagnosis of the condition related to such information.”101  Therefore, 
insurance companies are prohibited from refusing to enroll an individual or charging 
higher premiums based on information gleaned from that individual’s genetic profile.102  
Under HIPAA § 701(b)(1), insurance companies may only utilize genetic information if 
there has already been a confirmed diagnosis of disease.103 
¶33 Although the provisions contained in HIPAA that place strict standards on 
healthcare providers and insurance companies work well for genetic testing, these 
standards will not be strong enough to address privacy concerns once a 
pharmacogenomics database is developed.  Pharmacogenomics will require the use of 
genetic information before a condition has developed because researchers in this field 
evaluate the interactions of enzymes produced by genes, and not diseases resulting from 
the presence or absence of such genetic markers.104  In almost all cases, there will be an 
“absence of a diagnosis of the condition related”105 when researchers are using the 
genetic information to determine which drug is most effective and poses the least risk.  
Based on these considerations, it is necessary to amend HIPAA to explicitly include 
genetic databases. 
IV. PROPOSED SOLUTION: RECONCILING THE NEED FOR A GENETIC DATABASE WITH AN 
INDIVIDUAL’S RIGHT TO PRIVACY 
¶34 With the continuing concern over genetic privacy and potential discrimination, 
increased protections must be implemented in order to encourage individuals to 
 
99 Pub. L. No. 104-191, 110 Stat. 1936 (1996). 
100 Jeffrey N. Gibbs, State Regulation of Pharmaceutical Clinical Trials, 59 FOOD & DRUG L.J. 265, 266 
(2004). 
101 Section 701(a) provides that insurance companies may exclude coverage for a preexisting condition 
only under the following circumstances: 
(1) such exclusion relates to a condition (whether physical or mental), regardless of the cause of 
the condition, for which medical advice, diagnosis, care, or treatment was recommended or 
received within the 6-month period ending on the enrollment date; 
(2) such exclusion extends for a period of not more than 12 months (or 18 months in the case of 
a late enrollee) after the enrollment date; and 
(3) the period of any such preexisting condition exclusion is reduced by the aggregate of the 
periods of creditable coverage (if any, as defined in subsection (c)(1)) applicable to the 
participant or beneficiary as of the enrollment date. 
§ 701(a)(1-3), 110 Stat. at 1939. 
102 Id.; § 701(b)(1)(B), 110 Stat. at 1940. 
103 Id. 
104 See Silber, supra note 4, at 24. 
105 Pub. L. No. 104-191 § 701(b)(1)(B), 110 Stat. at 1940. 
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contribute their genetic information to a pharmacogenomics database.106  As discussed in 
Part III.a, comparisons of large numbers of genetic profiles are essential to the success of 
pharmacogenomics technology.107  Without some assurance that genetic information will 
not be used for discriminatory purposes, patients will be understandably reluctant to 
participate in the collection of data for a pharmacogenomics database.108  This section 
will discuss how the current law may be improved to address genetic privacy concerns in 
pharmacogenomics. 
A. Expanding HIPAA: The Need for a New Federal Law (or at least an addition to the 
old law) 
¶35 In order to protect an individual’s right to privacy once the pharmacogenomics 
database becomes a reality, Congress must pass a federal law to supplement HIPAA.  The 
law must be federal — although state law could adequately protect individuals, the 
database itself must be available nationally in order to improve its efficiency.109  
Uniformity is also necessary to ensure that all individuals contributing to the database are 
afforded the same protections and benefits under a federal law.110 
¶36 Establishing a new federal law to protect privacy concerns involving the 
pharmacogenomics database poses the question of whether this federal law should 
preempt state law.  HIPAA currently does not preempt state law where the state law 
provides greater privacy protections.111  Allowing more stringent privacy protections 
provided by state law may limit the amount of available information in a 
pharmacogenomics database, thereby decreasing the benefit to all who utilize the system.  
Therefore, such a provision may also reduce the efficiency of the system by limiting the 
number of people who contribute their profiles to the database.  A pharmacogenomics 
database would be most effective and provide the most material to evaluate drug efficacy 
and reactions if this proposed federal law preempted state law.112 
B. The Privacy Rule 
¶37 When HIPAA was passed in 1996, the statute required the Secretary of Health and 
Human Services to design standards for its implementation.113  In compliance with the 
 
106 See Greely, supra note 100, at 1500-01. 
107 See Silber, supra note 4, at 14. 
108 See Greely, supra note 100, at 1499-1502. 
109 Under HIPAA, states are currently allowed to implement more stringent standards supplementing 
federal law to protect genetic information without the possibility of preemption.  HIPAA IN PRACTICE: THE 
HEALTH INFORMATION MANAGER’S PERSPECTIVE 8 (American Health Information Management 
Association ed., 2004). 
110 One of the reasons for implementing HIPAA was to ensure uniformity among the states in protecting 
the confidentiality of health information.  Gina Marie Stevens, A Brief Summary of the HIPAA Medical 
Privacy Rule, CRS REPORT FOR CONGRESS RS20934 (2003).  Similarly, any addition to current law should 
represent a federal standard in order to continue uniformity of health information protection throughout the 
United States. 
111 HIPAA IN PRACTICE, supra note 112. 
112 See Greely, supra note 100, at 1501. 
113 Pub. L. No. 104-191 § 262, 110 Stat. at 1938. 
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Administrative Simplification provisions of the Act,114 the Secretary published the 
Standards for Privacy of Individually Identifiable Health Information on December 28, 
2000.115  These standards, more commonly referred to as the Privacy Rule, were finalized 
on August 14, 2002, and required health plan and health care provider compliance by 
April 13, 2003.116  The Privacy Rule states that HIPAA applies to group health plans 
covering more than fifty individuals and all health care providers, regardless of size, who 
transmit health information electronically.117 
¶38 The Privacy Rule allows health care providers to disclose information about their 
patients as long as there is a justification for doing so.118  The Privacy Rule “protects all 
‘individually identifiable health information’119 held or transmitted by a covered entity or 
its business associate, in any form or media, whether electronic, paper or oral,”120 which 
presumably includes genetic information. 
¶39 Although the Privacy Rule offers strong protections against the disclosure of 
information, the Rule also provides for situations in which disclosure is permissible.121  
Health care providers may disclose information for the “public good” without 
authorization by the patient.122  Under the public good exception, medical information 
may be disclosed without the patient’s consent to a public health authority for purposes of 
controlling or monitoring disease, or to government agencies such as the Food and Drug 
Administration (“FDA”) for evaluation of adverse drug reactions.123  It is this element of 
unauthorized disclosure that poses difficulties for the level of privacy needed for a 
successful pharmacogenomics database. 
 
114 Id. 
115 UNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICES OFFICE OF CIVIL RIGHTS PRIVACY 
BRIEF: SUMMARY OF THE HIPPA PRIVACY RULE 2 (May 2003), available at 
http://www.hhs.gov/ocr/privacysummary.pdf. 
116 Id. at 2, 18. 
117 Id. at 2. 
118 CAROLYN P. HARTLEY, MLA, CHP & EDWARD D. JONES III, HIPAA PLAIN & SIMPLE: A 
COMPLIANCE GUIDE FOR HEALTH CARE PROFESSIONALS 58 (2004). 
119 The Privacy Rule defines “individually identifiable health information” as: (1) information that is 
“created or received by a health care provider,” and (2) “relates to the past, present, or future physical or 
mental health or condition of an individual,” or relates to the provision of or payment for health care 
services by an individual, which identifies or may serve to identify that individual.  45 C.F.R. § 160.103 
(2005). 
120 Privacy Rule, supra note 118, at 3. 
121 A health care provider may disclose Protected Health Information (PHI) for the following 
purposes/situations: 
(1) To the individual when the individual when the information is her own; 
(2)  For use in treatment, payment or health care operations of the covered entity; 
(3)  When the patient has the opportunity to agree or object to disclosure; 
(4)  Disclosure is incidental to a permitted use or disclosure; 
(5)  For activities benefiting the public and in the public’s interest; or 
(6)  For research, public health, or health care operations (only limited data may be disclosed). 
Id. at 4-9.  See 45 C.F.R. § 164.512 (2005). 
122 Hartley, supra note 121, at 91. 
123 HIPPA IN PRACTICE, supra note 112, at 149.  Additionally, health care providers may disclose 
information in emergency situations, in cases of work-related illness, and to ensure compliance with 
OSHA.  Id. 
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¶40 The pharmacogenomics database is likely to fall under the “public good” exception 
to disclosure, thereby reducing an individual’s ability to exclude her information from the 
database.124  The pharmacogenomics database may qualify as a “public good” under any 
number of circumstances allowing disclosure without the individual’s consent, including 
disclosure to a public-health authority or the FDA, or disclosure for research purposes.125 
¶41 Because the pharmacogenomics database will be compiled for the good of the 
public in preventing adverse reactions and increasing drug efficacy, it is necessary to 
require informed consent of individuals who wish to include their profiles in the database.  
As the law stands now, the “public good” exception to confidentiality would allow 
researchers and compilers to obtain information that individuals desire to keep private.126  
Therefore, a provision governing the pharmacogenomics database and requiring informed 
consent must be included in a new federal law in order to protect the individual’s right to 
privacy. 
C. Access to Information Under the Proposed Law 
¶42 The current privacy law in the United States, as governed by HIPAA and related 
provisions promulgated under HIPAA such as the Privacy Rule, must be expanded to 
specifically address genetic information contained in databases like those required for the 
success of pharmacogenomics technology.  Once these provisions are expanded to protect 
against unauthorized disclosure of genetic information, access to a pharmacogenomics 
database must be granted not only to physicians and researchers, but also to insurance 
companies.  This would encourage growth and development of the system while also 
providing tangible financial benefits to the general public. 
¶43 With the development of a new pharmacogenomics database, it is important to 
determine who will have access to such a database, and codify these restrictions in new 
legislation.  Physicians and researchers would unequivocally require access to the 
pharmacogenomics database.  Physicians must access the database to aid in determining 
which drugs will cause the fewest side-effects and most effectively treat their patients’ 
conditions.  Researchers must also have the ability to access the database in order to 
make comparisons of genetic profiles to determine which genes affect drug-metabolizing 
enzymes.127 
¶44 Although it seems clear that physicians and researchers must have access to the 
pharmacogenomics database, other groups may want access as well.  Insurance 
companies are the most problematic of these groups, as discrimination by insurance 
agencies is one of the most foreseeable improper uses of an individual’s genetic 
information.128 
¶45 The argument for not granting access to insurance companies is based on the idea 
that insurance companies could utilize genetic information to deny coverage or to raise 
 
124 For research purposes, a health care provider may release health information without the consent of 
the patient as long as an institutional review board or privacy board approves a waiver of authorization.  
There are no other requirements.  JANE M. SULLIVAN, HIPAA: A PRACTICAL GUIDE TO THE PRIVACY AND 
SECURITY OF HEALTH DATA 45 (2004). 
125 45 C.F.R. § 164.512 (i-j). 
126 See SULLIVAN, supra note 127. 
127 See BROWN, supra note 1, at 191. 
128 See Barbara P. Fuller & Kathy Hudson, Genetic Information, in HARMAN, supra note 5, at 275. 
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premiums.129  However, even HIPAA prohibits insurance companies from using genetic 
information to evaluate coverage limitations and premiums, unless the patient has been 
diagnosed with a disease or condition.130  The proposed federal statute should follow 
HIPAA’s example in strongly protecting an individual’s right to keep genetic information 
private, especially when applied to the pharmacogenomics database. 
¶46 As long the proposed expansion of HIPAA is applied to information contained in 
the pharmacogenomics database, there are multiple advantages in allowing insurance 
companies to gain access to such information.  First, allowing access to such a database 
will ultimately result in lower premium costs for consumers by greatly diminishing the 
incentive for insurance companies to engage in reverse engineering.  Second, providing 
such access to insurance companies will benefit those companies financially, providing 
an incentive for the insurance industry to make financial contributions in support of the 
pharmacogenomics database.  Support from the insurance industry should ultimately 
cause the database to expand more quickly, resulting in tangible benefits to patients 
sooner rather than later.  However, these advantages will only occur if the insurance 
industry is forbidden from using genetic information to discriminate where the patient has 
not yet developed a disease or condition. 
1. Reducing Consumer Costs by Preventing Reverse Engineering of Genetic 
Information 
¶47 The potential new federal law governing the pharmacogenomics database must 
include access for insurance companies.  If access by insurance companies were 
restricted, it would likely lead to a sort of “reverse engineering.”  Reverse engineering 
typically appears in the context of trade secrets.131  An individual may purchase a product 
on the open market, then take it apart to see how it works, thus potentially revealing the 
trade secrets of the manufacturer.132  Reverse engineering may also apply in the context 
of the pharmacogenomics database.  Insurance companies may employ physicians or 
geneticists to determine the presence or absence of specific genes in an individual’s 
genetic profile based on the treatment prescribed by that individual’s physician for a 
given condition.  The insurance companies will waste money trying to determine, which 
of their customers have the potential for developing costly conditions.  Doing so may 
allow the insurance company to skirt the HIPAA provision preventing disclosure of 
genetic information, thereby providing an avenue for higher premiums or a denial of 
coverage. 
¶48 Although HIPAA explicitly states that premiums cannot be increased due to non-
diagnosed conditions,133 insurance companies may be able to determine genetic markers 
for specific diseases anyway through reverse engineering. Because of this, insurance 
companies should have full access to the pharmacogenomics database under the new law, 
which should retain HIPAA’s guard against the misuse of genetic information and 
 
129 Id. at 274-75. 
130 Pub. L. No. 104-191 § 701(b)(1)(B), 110 Stat. at 1940. 
131 See ROBERT P. MERGES ET AL., INTELLECTUAL PROPERTY IN THE NEW TECHNOLOGICAL AGE 66-67 
(2003). 
132 Id. at 49. 
133 Pub. L. No. 104-191 § 701(b)(1)(B), 110 Stat. at 1940. 
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expand it to specifically include the pharmacogenomics database.  Since HIPAA 
explicitly states that premiums cannot be increased due to non-diagnosed conditions,134 
people will not be penalized financially for the possibility that they will develop a genetic 
disease in the future. 
2. Financial Incentives for Insurance Companies Translate into Benefits for the 
Public 
¶49 The development of the pharmacogenomics database will not only help the public, 
but will also financially benefit the insurance industry.  The database, once it is fully-
operational, will reduce insurance companies’ expenditures.  As researchers determine 
with more accuracy which genes or gene combinations affect drug metabolism, 
physicians will be able to provide treatment options with more certainty.135  Experimental 
treatments and drugs, which are customarily more expensive, will be used less frequently, 
as patients will receive effective initial treatment of their condition.  Therefore, insurance 
companies will not be required to pay for multiple prescriptions or various expensive 
procedures in an effort to uncover a successful treatment for disease. 
¶50 Drug companies are already realizing a decrease in expenditures as a result of 
pharmacogenomics.136  During the early stages of clinical trials, drug companies are 
comparing genetic profiles of patients in order to determine which individuals react 
positively to the new drug.137  In the later stages of clinical trials, patients are pre-
screened to eliminate those individuals that may experience side effects or otherwise 
react poorly to the drug.138  As a result, new drugs may become available that would 
otherwise be declined due to side effects or lack of effectiveness for a large percentage of 
the population.139  Similarly, insurance companies will ultimately receive a financial 
benefit because the insured will only receive a particular medication if that individual’s 
genetic profile indicates a high degree of efficacy and a low risk of negative side 
effects.140 
¶51 Due to the strong financial benefit to insurance companies, it is less likely that 
insurance companies will take advantage of the pharmacogenomics database by using it 
to discriminate against their clients.  It is possible that the insurance industry may even 
contribute financially to the initial development of the database, or by providing 
incentives to those covered under their plans who donate their profiles.  Since the 
insurance industry will not benefit from the database until it is well-established, that 




135 See BROWN, supra note 1, at 185. 




140 Id. at 185. 
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V. CONCLUSION 
¶52 Pharmacogenomics will forever alter the way that physicians, patients, and the 
general public perceive genetic information.  In the near future, the expansion of 
pharmacogenomics will result in patients’ contribution of their genetic profiles to a 
database, enabling both themselves and the public to reap the benefits of a system that 
will most effectively distribute pharmaceuticals for treatment of all types of diseases and 
conditions.  Individuals will want to use the system in order to reduce the risk of 
unwanted side-effects and adverse drug reactions, as well as to increase the effectiveness 
of medications necessary to treat disease or relieve symptoms. 
¶53 The current manifestation of a pharmacogenomics database, PharmGKB, will 
probably not be sufficient to provide adequate comparisons of genetic profiles because 
(quick synopsis).  The new database, or modification to the existing PharmGKB 
database, must include entire genetic profiles, as most conditions and enzyme 
deficiencies reducing drug metabolism are now thought to be based in more than one 
gene.141 
¶54 It remains to be seen how the logistics of developing a new pharmacogenomics 
database will work out.  The National Institutes of Health is be the most likely candidate 
to run the database, as it has experience in the area of managing genetic databases with 
the Human Genome Project.  Other issues that need to be addressed include funding for 
the project, creation of software, and whether to require licensing of software. 
¶55 New legislation must be passed to enhance the privacy laws already in place.  This 
legislation must be federal and must include specific provisions for databases containing 
genetic material, as well as for collection, use, and distribution of information derived 
from an individual’s genetic profile.142  Databases of genetic material need not be 
protected more than other types of health information,143 but genetic information 
contained in databases must be expressly protected by federal legislation in order to 
ensure privacy rights.  New legislation should also include provisions requiring informed 
consent, as information collected for the pharmacogenomics database may be susceptible 
to the public good exception to the existing HIPAA Privacy Rule.  As individuals must 
have the ability to decide whether to include their genetic information in the 
pharmacogenomics database, informed consent must be required under the new law to 
prevent disclosure without the individual’s consent. 
¶56 The change in legislation must precede the changing technology in order to create 
the most efficient and beneficial pharmacogenomics system.  A new law governing the 
pharmacogenomics database need not be dramatically different from current privacy laws 
in the United States.  The scope of current law simply must be expanded to include 
patients’ rights to prevent their information from being publicly available on such a 
database, and to require informed consent under all circumstances.  The law should also 
include a provision encouraging individuals to register their genetic profiles on the 
database, as the greater the number of people who contribute, the more likely that the 
database will be a successful medical tool. 
 
141 SHARGEL, supra note 1, at 360. 
142 See Silber, supra note 4, at 14 (discussing the need for a comprehensive database). 
143 Fuller, supra note 131, at 276. 
